Drug Profile
Litifilimab - Biogen
Alternative Names: 24F4A; Anti-BDCA2 antibody - Biogen; BIIB-059Latest Information Update: 01 Jan 2024
Price :
$50
*
At a glance
- Originator Biogen Idec
- Developer Biogen
- Class Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action CLEC4C protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Cutaneous lupus erythematosus; Systemic lupus erythematosus
Most Recent Events
- 10 Nov 2023 Pharmacodynamics data from the phase II LILAC trial in Systemic lupus erythematosus presented at the ACR Convergence 2023 (ACR-ARP-2023)
- 20 Oct 2023 CTP Push 367499: updated trial initiation info in KDM and HE added
- 03 Oct 2023 Phase-III clinical trials in Cutaneous lupus erythematosus (Treatment-experienced) in USA (SC) (NCT06044337)